Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Public ClinicalTrials.gov record NCT02743351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Study identification
- NCT ID
- NCT02743351
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Fate Therapeutics
- Industry
- Enrollment
- 96 participants
Conditions and interventions
Conditions
Interventions
- ProTmune Biological
- Control Arm Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2016
- Primary completion
- Dec 3, 2020
- Completion
- Nov 4, 2021
- Last update posted
- Feb 7, 2023
2016 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | — | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California, San Diego (UCSD) Moores Cancer Center | San Diego | California | — | — |
| University of Chicago | Chicago | Illinois | — | — |
| Indiana Blood and Marrow Transplant | Indianapolis | Indiana | 46237 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Weill Cornell Medicine | New York | New York | — | — |
| Jewish Hospital | Cincinnati | Ohio | — | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | — | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Transplant Institute | San Antonio | Texas | — | — |
| Huntsman Cancer Institute (University of Utah) | Salt Lake City | Utah | 84103 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02743351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02743351 live on ClinicalTrials.gov.